Use of Daptomycin to Manage Severe MRSA Infections in Humans

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Microbiology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant therapeutic challenge due to multidrug resistance.
• Daptomycin (DAP) is a key antibiotic for severe MRSA infections, known for rapid bactericidal activity and a favorable safety profile.

Purpose of the Study:

• To review studies on daptomycin for MRSA infections from 2010 to April 2025.
• To evaluate high-dose DAP efficacy, combination therapies, and resistance patterns.

Main Methods:

• Narrative review of published studies (2010-April 2025).
• Analysis of clinical data on daptomycin dosing, combination therapies (fosfomycin, β-lactams), and resistance mechanisms.

Main Results:

• High-dose (8-10 mg/kg) DAP shortened blood-culture sterilization time by 2 days compared to vancomycin without increased toxicity with AUC monitoring.
• Daptomycin combined with fosfomycin or β-lactams (ceftaroline, ceftobiprole) showed synergistic effects, reducing microbiological failure in persistent MRSA infections.
• MRSA resistance to daptomycin remains uncommon (<2%), but mutations in *mprF*, *liaFSR*, and *walK* highlight the need for genomic surveillance.

Conclusions:

• Daptomycin is a critical option for MRSA management, especially with precision dosing and AUC monitoring.
• Combination strategies show promise but require further randomized controlled trials for definitive clinical practice guidelines.
• Antimicrobial stewardship, resistance surveillance, and cost-effectiveness evaluations are essential for optimizing daptomycin use.